<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacology of amphotericin B</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacology of amphotericin B</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pharmacology of amphotericin B</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Drew, PharmD, MS, FCCP, FIDP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Amphotericin B is a polyene antifungal agent with activity in vitro against a wide variety of fungal pathogens [<a href="#rid1">1</a>]. Amphotericin B exerts its antifungal effect by disruption of fungal cell wall synthesis because of its ability to bind to sterols, primarily ergosterol, which leads to the formation of pores that allow leakage of cellular components. This affinity may also account for its toxic effects against select mammalian cells. Amphotericin B is generally considered cidal against susceptible fungi at clinically relevant concentrations.</p><p>Despite the introduction of newer antifungal agents for the treatment of systemic mycoses, amphotericin B remains the standard treatment for many severe, invasive fungal infections. However, because of toxicities associated with its intravenous use, along with the expanded availability of safer treatment options, it is frequently reserved for patients who have severe, life-threatening invasive fungal infections or who are unable to tolerate alternative antifungal agents. With the exception of neonatal candidiasis and treatment of <em>Candida</em> urinary tract infections, lipid-based formulations (most notably <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a>) have largely replaced <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> due to their improved tolerability [<a href="#rid2">2,3</a>].</p><p>The pharmacology of amphotericin B will be reviewed here. The nephrotoxicity and the clinical uses of amphotericin B (including the potential role as part of combination therapy) are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity"</a> and  <a class="medical medical_review" href="/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a> and  <a class="medical medical_review" href="/d/html/2425.html" rel="external">"Chronic disseminated candidiasis (hepatosplenic candidiasis)"</a> and  <a class="medical medical_review" href="/d/html/2415.html" rel="external">"Candida infections of the bladder and kidneys"</a> and  <a class="medical medical_review" href="/d/html/2466.html" rel="external">"Candida osteoarticular infections"</a> and  <a class="medical medical_review" href="/d/html/2446.html" rel="external">"Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species"</a> and  <a class="medical medical_review" href="/d/html/16220.html" rel="external">"Treatment of exogenous endophthalmitis due to Candida species"</a> and  <a class="medical medical_review" href="/d/html/2423.html" rel="external">"Candida endocarditis and suppurative thrombophlebitis"</a> and  <a class="medical medical_review" href="/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a> and  <a class="medical medical_review" href="/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/d/html/15674.html" rel="external">"Treatment and prevention of Fusarium infection"</a> and  <a class="medical medical_review" href="/d/html/2443.html" rel="external">"Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in patients without HIV"</a> and  <a class="medical medical_review" href="/d/html/3757.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV"</a> and  <a class="medical medical_review" href="/d/html/2421.html" rel="external">"Cryptococcus neoformans infection outside the central nervous system"</a> and  <a class="medical medical_review" href="/d/html/2463.html" rel="external">"Treatment of blastomycosis"</a> and  <a class="medical medical_review" href="/d/html/2451.html" rel="external">"Diagnosis and treatment of pulmonary histoplasmosis"</a> and  <a class="medical medical_review" href="/d/html/2461.html" rel="external">"Diagnosis and treatment of disseminated histoplasmosis in patients without HIV"</a> and  <a class="medical medical_review" href="/d/html/6996.html" rel="external">"Treatment of histoplasmosis in patients with HIV"</a> and  <a class="medical medical_review" href="/d/html/2444.html" rel="external">"Management of pulmonary sequelae and complications of coccidioidomycosis"</a> and  <a class="medical medical_review" href="/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis"</a> and  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients"</a> and  <a class="medical medical_review" href="/d/html/2445.html" rel="external">"Coccidioidal meningitis"</a> and  <a class="medical medical_review" href="/d/html/2431.html" rel="external">"Treatment of sporotrichosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SPECTRUM OF ACTIVITY</span><span class="headingEndMark"> — </span>Activity of amphotericin B has been demonstrated in vitro against a wide variety of clinical fungal isolates, including most <em>Candida </em>spp, <em>Aspergillus </em>spp, the Mucorales [<a href="#rid4">4</a>], all of the endemic mycoses, and most hyaline and brown-black molds. Activity has also been demonstrated against <em>Leishmania</em> spp [<a href="#rid5">5</a>].</p><p>Fungal pathogens that are usually resistant to amphotericin B include the organisms that cause chromoblastomycosis, <em>Aspergillus terreus</em>, <em>Candida lusitaniae</em>, <em>Scedosporium </em>spp, and some <em>Fusarium </em>spp [<a href="#rid5">5-9</a>]. </p><p><em>Candida auris</em> is an emerging fungal pathogen considered to be a serious global threat [<a href="#rid10">10</a>]. There are no Clinical and Laboratory Standards Institute (CLSI) amphotericin B interpretive breakpoints available for <em>C. auris</em>. Therefore, tentative susceptibility testing breakpoints are based on other <em>Candida</em> species. The US Centers for Disease Control and Prevention (CDC) currently utilize a tentative breakpoint of &gt;2 mcg/mL (or an Etest<sup>®</sup> result of 1.5 mcg/mL) as resistant [<a href="#rid11">11</a>]. Based on these criteria, about 30 percent have been resistant to amphotericin B [<a href="#rid11">11</a>]. The potential role of amphotericin B (alone or as part of combination therapy) [<a href="#rid12">12,13</a>] in the treatment of <em>C. auris</em> is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p class="headingAnchor" id="H102701911"><span class="h1">PHARMACODYNAMICS</span><span class="headingEndMark"> — </span>Based primarily on data from murine disseminated candidiasis models, amphotericin B is thought to exhibit concentration-dependent fungicidal activity. A prolonged post-antifungal effect has been demonstrated against some <em>Candida</em> species [<a href="#rid14">14,15</a>]. Neutropenic mouse models of both disseminated candidiasis and pulmonary aspergillosis described correlations between peak concentration (C<sub>max</sub>) to minimum inhibitory concentration (MIC) ratios and outcome [<a href="#rid16">16-19</a>].</p><p class="headingAnchor" id="H248502"><span class="h1">AMPHOTERICIN B DEOXYCHOLATE</span></p><p class="headingAnchor" id="H3"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Despite several decades of clinical use, relatively little is known about the pharmacokinetics of amphotericin B [<a href="#rid20">20</a>]. The pharmacokinetic profiles of the lipid-based formulations of amphotericin B differ from those of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> and from each other. (See <a class="local">'Lipid-based amphotericin B formulations'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h3">Absorption</span><span class="headingEndMark"> — </span>The drug is poorly absorbed (less than 5 percent) after oral administration. As a result, treatment of invasive mycoses requires intravenous (IV) administration. An oral suspension (no longer commercially available in the United States) is useful only in the treatment of oropharyngeal candidiasis and is generally reserved for those infections that are refractory to other agents. Systemic absorption following aerosol administration is also thought to be minimal.</p><p class="headingAnchor" id="H5"><span class="h3">Distribution</span><span class="headingEndMark"> — </span>Serum concentrations following IV infusions of 30 to 50 mg of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> have ranged from 1 to 2 mcg/mL. The drug is highly protein bound (up to 95 percent), primarily to lipoproteins. It is extensively distributed throughout the body, with a volume of distribution of approximately 4 L/kg.</p><p>Amphotericin B concentrations can be measured in various body tissues and fluids, including liver, spleen, pleural fluid, peritoneal fluid, joint, vitreous body, and aqueous humor. Poor penetration into inflamed and uninflamed meninges has been reported, despite demonstrated clinical efficacy in central nervous system fungal infections, such as cryptococcal meningitis and other fungal infections [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Metabolism/elimination</span><span class="headingEndMark"> — </span>No metabolites have been identified. Drug elimination is biphasic, with a terminal half-life of up to 15 days. Like volume of distribution, clearance demonstrates a linear relationship to weight [<a href="#rid21">21</a>]. The primary route of elimination of amphotericin B is not known; urine and biliary excretion account for less than 5 percent of the administered dose. Serum concentrations are not influenced by hepatic or renal function or by hemodialysis or peritoneal dialysis.</p><p class="headingAnchor" id="H7"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>Treatment doses of IV <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> range from 0.5 to 1.5 mg/kg per day. Doses of 0.1 mg/kg per day of amphotericin B deoxycholate have been investigated as prophylaxis in high-risk patients [<a href="#rid22">22,23</a>]. However, this practice has largely been replaced by alternative agents with less toxicity. </p><p>The usual dose of IV <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> for most invasive mycoses is 0.5 to 1 mg/kg per day. Doses exceeding 1 mg/kg per day are generally reserved for treatment of mucormycosis and azole-refractory invasive coccidioidomycosis (such as meningitis). Daily doses of 1.5 mg/kg per day should not be exceeded. Pathogen- and disease-specific dosing recommendations have been published by the Infectious Diseases Society of America (IDSA) for many invasive mycoses [<a href="#rid24">24</a>]. The recommended dosing of amphotericin B for each fungal disease and infection site is discussed in detail separately. (See relevant topic reviews.)</p><p>The dose of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> does not need to be adjusted for renal dysfunction. In the setting of renal dysfunction, alternate-day therapy of twice the daily dose has historically been described. However, with the advent of lipid-based formulations, such a dosing strategy is rarely employed in current practice. No dosage adjustment or supplemental dose is recommended in patients receiving concomitant renal replacement therapy.</p><p>The dosing of lipid-based formulations of amphotericin B is discussed below. (See <a class="local">'Dosing'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Method of administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">Amphotericin B deoxycholate</a> is most commonly administered intravenously, but direct or local instillation has been used in several clinical circumstances [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H439193761"><span class="h3">Intravenous</span><span class="headingEndMark"> — </span>IV infusions are prepared by combining <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> with 5% dextrose in water (D5W) at a final concentration of 0.1 mg/mL. Although the incidence of acute hypersensitivity reactions from amphotericin B is rare, a test dose of 1 mg has been recommended. The test dose can be given as an aliquot of the initial infusion, followed by the remainder of the dose if there is no apparent reaction within 30 minutes. However, tolerance of the test dose does not exclude other amphotericin B toxicities.</p><p>Infusion times are traditionally four to six hours. Amphotericin B has been given over shorter time periods (eg, 45 to 60 minutes), but infusion-related reactions (such as fever) may be more frequent, and this method is not recommended [<a href="#rid26">26</a>]. The practice of titrating the daily dose to the target dose over several days has not been proven to lessen adverse reactions and may delay optimal therapy.</p><p>IV administration of the total daily dose of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> given as a continuous infusion over 24 hours (when combined with therapeutic drug monitoring) has been associated with less nephrotoxicity compared with administration over four hours [<a href="#rid27">27,28</a>]. However, the efficacy of this administration schedule for patients with established infections has not been proven in controlled clinical trials. Furthermore, amphotericin B exhibits concentration-dependent pharmacodynamics that may be compromised by continuous infusion. Continuous infusion of amphotericin B is not US Food and Drug Administration (FDA) approved and is not currently recommended.</p><p>Administration of premedications to patients receiving amphotericin B should be considered to prevent infusion-related reactions and nephrotoxicity. (See <a class="local">'Adverse effects'</a> below.)</p><p class="headingAnchor" id="H439193603"><span class="h3">Bladder irrigation</span><span class="headingEndMark"> — </span>Irrigation of the bladder with <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> has been used in the treatment of candiduria. There have been several nonblinded randomized trials comparing amphotericin B bladder irrigation with oral <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid29">29,30</a>]. Although the use of amphotericin B bladder irrigation resulted in clearing of candiduria in many patients, relapses were routinely observed after several weeks. Traditionally, 50 mg of amphotericin B has been added to 1000 mL sterile water for irrigation and given as a continuous bladder irrigation daily for a period of five days. However, this regimen requires the presence of an indwelling bladder catheter, which itself is a risk factor for candiduria. Shorter treatment courses (one day) or reduced doses (as low as 5 mg/day) have been recommended by some authors [<a href="#rid31">31,32</a>].</p><p>Published guidelines on the treatment of candiduria do not recommend the routine use of amphotericin B bladder irrigation, except in exceptional circumstances, such as treatment of adult nonneutropenic patients with symptomatic cystitis due to fluconazole-resistant species (<em>Candida glabrata</em>, <em>Candida krusei</em>) [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/2415.html" rel="external">"Candida infections of the bladder and kidneys", section on 'Fluconazole-resistant Candida'</a>.)</p><p class="headingAnchor" id="H439193798"><span class="h3">Intraperitoneal</span><span class="headingEndMark"> — </span>Local instillation of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> has also been reported in the treatment of fungal peritonitis (alone or in combination with IV therapy). This practice is discouraged because it causes abdominal pain and can contribute to adhesion formation and loss of the peritoneum as a dialyzing membrane. Patients with fungal peritonitis should be treated with catheter removal and systemic antifungal therapy [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H463493101"><span class="h3">Intrathecal</span><span class="headingEndMark"> — </span>Intrathecal administration of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> in the lumbar subarachnoid space has been used primarily for the treatment of coccidioidal meningitis. Target doses generally range from 0.1 to 1.5 mg at intervals ranging from daily to weekly [<a href="#rid33">33</a>]; lower doses (ie, 0.01 mg) can be started and increased slowly until target doses are reached or the patient shows signs of intolerance [<a href="#rid34">34</a>]. Adverse effects resulting from intrathecal administration are frequent and include, but are not limited to, nausea and vomiting, headache, back and/or leg pain, loss of bowel and/or bladder control, and nerve palsies. The development of arachnoiditis is a serious complication of this form of therapy.</p><p>Intrathecal <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> can also be given through a ventricular Ommaya or Rickham reservoir. The target dose range is the same as for intrathecal administration in the lumbar subarachnoid space (0.1 to 1.5 mg daily to weekly). Severe vomiting, headache, and prostration can occur, and bacterial infection of the reservoir has been reported.</p><p>Cisternal administration of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, either through a reservoir or by direct injection, is used in some cases of coccidioidal meningitis in order to attain drug levels in the basilar meninges, where the infection is localized [<a href="#rid33">33</a>]. The dose range is the same as for intrathecal and intraventricular administration noted above. Severe headache, vomiting, prostration, and even death have been reported following intracisternal injection of amphotericin B [<a href="#rid33">33,35</a>]. Only experts at cisternal injections should undertake this form of therapy. (See  <a class="medical medical_review" href="/d/html/2445.html" rel="external">"Coccidioidal meningitis", section on 'Antifungal therapy'</a>.)</p><p class="headingAnchor" id="H439193919"><span class="h3">Intravitreal</span><span class="headingEndMark"> — </span>Intravitreal and intracameral (into the aqueous humor) injection of amphotericin B has been used to treat fungal endophthalmitis. (See  <a class="medical medical_review" href="/d/html/2446.html" rel="external">"Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species"</a> and  <a class="medical medical_review" href="/d/html/16205.html" rel="external">"Treatment of endophthalmitis due to molds"</a>.)</p><p class="headingAnchor" id="H439193863"><span class="h3">Aerosolized/nebulized</span><span class="headingEndMark"> — </span>Administration of aerosolized (nebulized) amphotericin B (notably <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, <a class="drug drug_general" data-topicid="8724" href="/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a>, and <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a>) has been reported as a potential strategy in the prevention of invasive fungal infections in select patient populations, such as patients with hematologic malignancies and lung transplant recipients [<a href="#rid16">16</a>]. It has also been used for secondary prophylaxis in patients with allergic bronchopulmonary aspergillosis (ABPA) [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/16141.html" rel="external">"Prophylaxis of invasive fungal infections in adults with hematologic malignancies", section on 'Amphotericin B'</a> and  <a class="medical medical_review" href="/d/html/1394.html" rel="external">"Fungal infections following lung transplantation", section on 'Prophylaxis'</a>.)</p><p>Less frequently, aerosolized (nebulized) formulations of amphotericin B have been used as adjunctive therapy (in combination with systemic antifungal therapy) in the treatment of invasive fungal infections of the lung that are refractory to standard therapy or in patients intolerant of standard therapy [<a href="#rid17">17,37,38</a>].</p><p class="headingAnchor" id="H3393444035"><span class="h3">Antibiotic lock</span><span class="headingEndMark"> — </span>Antibiotic lock therapy for catheter-related bloodstream infections (CRBSIs) refers to the instillation of a highly concentrated antibiotic solution (with or without heparin) into the intravascular catheter, which is allowed to dwell within the catheter while not in use and is then removed prior to catheter use. (See  <a class="medical medical_review" href="/d/html/13982.html" rel="external">"Lock therapy for treatment and prevention of intravascular non-hemodialysis catheter-related infection"</a>.)</p><p>In general, management of CRBSIs due to fungi consists of catheter removal and systemic antifungal therapy. However, use of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> as an antibiotic lock solution in intravenous and peritoneal dialysis catheters for line salvage as an option to catheter removal has been described. Concentrations of amphotericin B deoxycholate reported range from 0.33 to 2.5 mg/mL, most commonly 2.5 mg/mL [<a href="#rid39">39-46</a>]. In such settings, amphotericin B should be diluted with D5W, not normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>. Dwell times are usually about 8 hours and should not exceed 12 hours. Limited experience with <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> in this setting at a concentration of 2 mg/mL (allowed to dwell for 8 to 12 hours daily and then withdrawn) has also been published [<a href="#rid47">47-49</a>]. </p><p>Antibiotic lock therapy is strongly discouraged for tunneled hemodialysis catheters that are colonized/infected with fungi, and in nearly all cases, the infected catheter should be removed. (See  <a class="medical medical_review" href="/d/html/1966.html" rel="external">"Tunneled hemodialysis catheter-related bloodstream infection (CRBSI): Management and prevention"</a>.) </p><p class="headingAnchor" id="H9"><span class="h2">Adverse effects</span></p><p class="headingAnchor" id="H10"><span class="h3">Infusion-related reactions</span><span class="headingEndMark"> — </span>Infusion-related reactions, particularly nausea, vomiting, chills, and rigors, are common with IV <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> administration, usually occurring either during infusion (within 15 minutes to 3 hours following initiation) or immediately following administration of the dose. Treatment of amphotericin B-related nausea and vomiting (as well as prevention of subsequent reactions) may require the use of a phenothiazine (eg, <a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">promethazine</a>, <a class="drug drug_general" data-topicid="9816" href="/d/drug information/9816.html" rel="external">prochlorperazine</a>,) or <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a>. </p><p>Phlebitis is a complication that primarily occurs in patients receiving infusions via a small peripheral vein. The addition of <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> (usual adult dose 25 mg) or heparin (usual final concentration 500 to 1000 U/L) to the infusion may lessen infusion-related thrombophlebitis, but trials to establish their efficacy are lacking and these adjuncts are not recommended [<a href="#rid5">5</a>].</p><p>Other ways to minimize thrombophlebitis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Infusion of the drug using a central line</p><p class="bulletIndent1"><span class="glyph">●</span>Use of alternating infusion sites</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of final amphotericin B infusion concentrations exceeding 0.1 mg/mL</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of infusion times of less than four hours</p><p></p><p>Drug-induced fever, chills, and headache can also be seen. These symptoms can be minimized or prevented by premedication with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and/or <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, Nonsteroidal anti-inflammatory agents may also be useful in this setting. In a double-blind, placebo-controlled trial, <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> administered 30 minutes prior to <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> reduced the rate of occurrence of chills from 87 percent to 49 percent [<a href="#rid50">50</a>]. <a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">Meperidine</a> may reduce amphotericin B-induced chills and rigors. However, meperidine is not routinely recommended for premedication due to its potential side effects. </p><p class="headingAnchor" id="H11"><span class="h3">Nephrotoxicity</span><span class="headingEndMark"> — </span>IV administration of any formulation of amphotericin B may result in nephrotoxicity. With <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, a reversible and often transient decline in glomerular filtration rate (GFR) has been described in 5 to 80 percent of patients (depending largely on the patient population, definition of nephrotoxicity, and the formulation utilized). The net effect is an elevation (above baseline) in the serum creatinine concentration. Severe renal failure due to amphotericin B deoxycholate alone is less common, but the risks of such reactions increase with diuretic-induced volume depletion or the concurrent administration of another nephrotoxin (such as an aminoglycoside, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, nephrotoxic cancer chemotherapy, or <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a>). Amphotericin B deoxycholate is substantially more nephrotoxic than the lipid-based formulations of amphotericin B. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity"</a>.)</p><p>Even though adequately controlled human clinical data to support such a practice is limited, volume expansion with IV sodium chloride (a practice commonly known as "sodium loading") may ameliorate the decline in GFR. In the absence of contraindications, a total of 500 mL of 0.9 percent sodium chloride is typically given immediately prior to the amphotericin B infusion or divided before and after amphotericin B administration. Such strategies, however, may not be effective or practical in patients with critical illness with preexisting renal dysfunction [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity", section on 'Salt loading'</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Electrolyte abnormalities</span><span class="headingEndMark"> — </span>Hypokalemia, hypomagnesemia, and hyperchloremic acidosis are reflections of an increase in distal tubular membrane permeability following IV administration of amphotericin B. Many patients require significant amounts of potassium and/or magnesium supplementation during therapy. Correction of hypokalemia may be difficult in patients with persistent hypomagnesemia and early and aggressive electrolyte repletion is often required. (See  <a class="medical medical_review" href="/d/html/848.html" rel="external">"Hypomagnesemia: Clinical manifestations of magnesium depletion"</a> and  <a class="medical medical_review" href="/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity", section on 'Electrolyte and acid-base disorders'</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Other reactions</span><span class="headingEndMark"> — </span>A reversible, normochromic, normocytic anemia occurs in most patients receiving IV amphotericin B, but the onset may be delayed for as long as 10 weeks after the initiation of therapy [<a href="#rid26">26</a>]. Other hematologic side effects have also been described, including severe leukopenia [<a href="#rid52">52</a>]. Transfusions are infrequently required. Elevations in liver function tests have been associated with amphotericin B administration infrequently.</p><p>Severe allergic reactions (including anaphylaxis) are extremely rare but have been reported.</p><p class="headingAnchor" id="H14"><span class="h2">Patient monitoring</span><span class="headingEndMark"> — </span>Patients receiving amphotericin B intravenously should be monitored clinically for infusion-related reactions during and following each administration. Measurements of renal function should be performed daily during initiation of therapy (up to two weeks) and at least weekly thereafter, if stable. Some experts recommend that amphotericin B administration be held or a lipid-based formulation substituted if the plasma creatinine concentration exceeds 2.5 mg/dL (265 micromol/L).</p><p>Serum electrolytes (particularly potassium and magnesium) should be assessed at baseline and at least twice weekly throughout therapy. More frequent monitoring is recommended for patients experiencing hypokalemia and hypomagnesemia as a result of amphotericin B administration. Complete blood counts should be measured weekly throughout therapy. Monitoring of liver function tests is usually not necessary unless the patient has clinical signs or symptoms suggesting hepatic toxicity.</p><p>Increasing attention has been made to the monitoring of antifungal serum concentrations (more commonly known as therapeutic drug monitoring [TDM]) [<a href="#rid53">53</a>]. However, in contrast to many of the azole antifungals (most notably <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>), established serum concentration targets are presently lacking for amphotericin to optimize efficacy while minimizing toxicity, and serum amphotericin B levels are unavailable to most clinicians.</p><p class="headingAnchor" id="H16"><span class="h1">LIPID-BASED AMPHOTERICIN B FORMULATIONS</span><span class="headingEndMark"> — </span>Lipid-based formulations of amphotericin B have been introduced in an attempt to reduce the toxicities associated with <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> [<a href="#rid54">54,55</a>]. Based on animal models and clinical studies, these formulations reduce the risk of amphotericin B-related nephrotoxicity. In a meta-analysis, the efficacy of amphotericin B deoxycholate and lipid-based formulations was similar [<a href="#rid56">56</a>]. The nephrotoxicity of amphotericin B is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity"</a>.)</p><p>The available lipid-based formulations are <a class="drug drug_general" data-topicid="8724" href="/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> (ABLC; Abelcet) and <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (AmBisome) [<a href="#rid57">57,58</a>]. Due largely to their improved safety (most notably decreased nephrotoxicity), the lipid-based formulations have replaced <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> in many invasive fungal infection treatment guidelines.</p><p class="headingAnchor" id="H17"><span class="h2">Safety and efficacy</span><span class="headingEndMark"> — </span>Few randomized, comparative studies are available that directly compare the safety and efficacy of these formulations to <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> intravenously. Controlled studies establishing the treatment efficacy of these agents are somewhat limited and often involve patients previously treated with amphotericin B deoxycholate [<a href="#rid59">59</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of randomized trials, the incidence of nephrotoxicity was significantly lower with <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> compared with <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (15 versus 33 percent) [<a href="#rid60">60</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial comparing the efficacy of <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> with <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> for the treatment of severe disseminated histoplasmosis in 81 AIDS patients, the liposomal formulation resulted in a higher rate of clinical success (88 versus 64 percent) and lower mortality (2 versus 13 percent) [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trial comparing <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> to <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> for empiric therapy in patients with persistent fever and neutropenia found no difference in composite rates of successful treatment and patient outcomes [<a href="#rid62">62</a>]. However, significantly fewer patients given liposomal amphotericin B had breakthrough fungal infections, infusion-related fever, chills or rigors, or nephrotoxicity. This was the first trial to note a reduction in infusion-related reactions associated with the liposomal formulation of amphotericin B.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study comparing ABLC (5 mg/kg per day) and <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (3 or 5 mg/kg per day) as empiric therapy in patients with febrile neutropenia persisting after 72 hours of antibacterial treatment reported equivalent clinical outcome but reduced toxicity in the liposomal amphotericin B group at both doses compared with ABLC [<a href="#rid63">63</a>]. Fever, chills and rigors, nephrotoxicity, and toxicity-related discontinuation of therapy were all reduced in the liposomal amphotericin B group, although all of the infusion reactions except chills and rigors decreased after the first day in the ABLC-treated patients.</p><p></p><p>Studies comparing lipid-based formulations for safety are sparse and are generally limited to observational, uncontrolled trials. In one such study of patients with invasive coccidioidomycosis, <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> appeared to have less nephrotoxicity than ABLC [<a href="#rid64">64</a>].</p><p><a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">Liposomal amphotericin B</a> has a lower incidence of infusion-related reactions than <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>. However, a unique group of infusion reactions can occur with liposomal amphotericin B, which have not been observed with <a class="drug drug_general" data-topicid="8724" href="/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a>; a type 1 hypersensitivity reaction (labeled as complement activation-related pseudoallergy [CARPA]) is thought to be a consequence of complement activation with resulting mast cell and basophil secretory response [<a href="#rid65">65-67</a>]. Symptoms develop within five minutes and include chest pain, dyspnea, hypoxia, abdominal pain, flushing, and urticaria and generally respond to stopping the infusion as well as therapy with <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> [<a href="#rid66">66,68</a>].</p><p>Infusion-related intolerance to one formulation may not predict similar reactions to other formulations [<a href="#rid63">63,69</a>]. As an example, ABLC administration was uneventful in 34 of 40 patients (85 percent) who had previous severe reactions to <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> in one retrospective study [<a href="#rid69">69</a>]. Premedication with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a>, and/or <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> was used in many patients.</p><p>Electrolyte abnormalities, such as hypokalemia, hypomagnesemia, and hyperchloremic acidosis, may occur following the administration of both lipid-based and deoxycholate formulations of amphotericin B (see <a class="local">'Electrolyte abnormalities'</a> above). False elevations of serum phosphate may occur when samples from patients receiving AmBisome are analyzed using the PHOSm assay used in Beckman Coulter analyzers, including the Synchron LX20 [<a href="#rid70">70</a>]. Assessments of C-reactive protein may also be impacted by lipid-based formulations of amphotericin B; notably <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> can produce false declines in serum/plasma CRP concentration [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Lipid-based formulations of amphotericin B differ significantly in pharmacokinetic profile from <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> and from each other [<a href="#rid54">54,72</a>]. As an example, ABLC appears to be taken up rapidly by the reticuloendothelial system and demonstrates high tissue distribution, lower serum concentrations, and a prolonged elimination half-life when compared with <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a>. By contrast, liposomal amphotericin B demonstrates a significantly lower volume of distribution, which results in high serum concentrations, and a shorter elimination half-life than does ABLC or amphotericin B deoxycholate [<a href="#rid65">65,72</a>]. Studies in morbidly obese patients demonstrate limited distribution into adipose tissue [<a href="#rid73">73</a>]. Liposomal amphotericin B localizes in lung epithelial lining fluid, within liver and splenic macrophages, and in kidney distal tubules.</p><p>Significant intra- and inter-subject variability in the pharmacokinetic profiles of lipid-based formulations have also been reported in special populations, such as <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> pharmacokinetics in patients with critical illness [<a href="#rid74">74,75</a>].</p><p>Although lipid formulations of amphotericin B reach detectable concentrations in pleural fluid, these concentrations are often below the minimum inhibitory concentration required for some yeasts and dimorphic fungi [<a href="#rid76">76</a>].</p><p>The impact of dose escalation on the pharmacokinetics of <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (&gt;10mg/kg/day) has been investigated. In prior reports, doses of LAmB exceeding 10mg/kg/day demonstrated nonlinear (saturable) pharmacokinetics [<a href="#rid77">77,78</a>]. More recently, a variety of doses of liposomal amphotericin B were studied in adult patients with HIV and cryptococcal meningitis, and [<a href="#rid79">79</a>].no evidence of nonlinear kinetics at this dose and frequency were observed.</p><p class="headingAnchor" id="H1045108273"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>Lipid formulations of amphotericin B are generally administered in hospital settings and standard doses are used. In rare selected circumstances (eg, outpatient treatment), higher doses and/or extended interval dosing can be used. When alternative dosing regimens are used, an expert in the treatment of fungal infections should be consulted. </p><p class="headingAnchor" id="H3770019824"><span class="h3">Standard dosing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Typical adult dosing</strong> − Doses of ABLC are generally 5 mg/kg per day. The dose of <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> usually ranges from 3 to 5 mg/kg per day (depending upon the indication). Dosing for specific indications is discussed in specific UpToDate topics and in Lexicomp drug monographs. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pediatric dosing</strong> − Studies of <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> in children indicate that comparable weight-based dosing can be used in this population [<a href="#rid77">77</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic and renal dysfunction</strong> − No dosing adjustment is recommended for <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> in the setting of either hepatic or renal insufficiency. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal replacement therapy</strong> − No dosing adjustment is recommended in the setting of renal replacement therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracorporeal membrane oxygenation (ECMO)</strong> − Because <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> is highly lipophilic and highly protein bound, sequestration of drug within the ECMO circuit is possible. However, data in this population are generally limited to case reports [<a href="#rid80">80,81</a>]. One such report describes an adult with blastomycoses treated with L-AMB (5 mg/kg/day) who was initiated on ECMO and concurrent continuous renal replacement therapy (CRRT) [<a href="#rid80">80</a>]. Serum concentrations were obtained after a dose increase to 10mg/kg/day. When compared to external data in non-ECMO patients at a similar dose, the investigators reported an approximate 50 percent decrease in observed peak concentration (Cmax), a more than doubled volume of distribution (Vd) and slightly increased drug clearance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity </strong>− Optimal dosing of lipid-based formulations of amphotericin B in morbidly obese patients is unknown. In one trial examining doses of 1 mg/kg and 2 mg/kg of <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> in 16 individuals with a body mass index &gt;40 kg/m<sup>2</sup>, the drug’s clearance was independent of weight [<a href="#rid73">73</a>]. Investigators proposed that a maximum dosing weight of 100 kg be used in patients ≥100 kg and would therefore receive a fixed dose of either 300 or 500 mg (corresponding to weight-based dosing of 3 and 5 mg/kg, respectively). However, results of such studies are impacted by the formulation studied, limited sample population, and the complex nature of drug release from the liposomes, among other factors [<a href="#rid82">82</a>]. </p><p></p><p class="bulletIndent1">In patients receiving <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> whose total body weight (TBW) exceeds 120 percent of their ideal body weight (IBW), receipt of 5mg/kg based on TBW (when compared to use of adjusted body weight [adjBW]) experienced higher rates of nephrotoxicity (57 versus 35 percent, respectively [P value of 0.016]) and early discontinuation of LAmB due to toxicity (33 versus 17 percent [P = 0.030]) [<a href="#rid83">83</a>]. However, given a trend toward increased 90-day mortality in the adjBW group relative to the TBW group (60 versus 45 percent respectively, [P = 0.079]), the higher doses resulting from TBW-based dosing are likely justified in those critically ill with severe, potentially life-threatening infection. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – the optimal dosing weight (IBW versus actual body weight versus adjBW) in pregnant women is not addressed in present treatment guidelines. In one case report, IBW was utilized for the treatment of mucocutaneous leishmaniasis [<a href="#rid84">84</a>]. </p><p></p><p class="headingAnchor" id="H4237722077"><span class="h3">Alternative strategies</span><span class="headingEndMark"> — </span>In rare selected circumstances, higher doses and/or extended interval dosing can be used. When designing an alternative dosing regimen, an expert in the treatment of fungal infections should be consulted. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transition to outpatient therapy </strong>−<strong> </strong>Extended-interval dosing has been reported to be effective for patients who have a documented response to initial daily therapy in hospital and who require continued treatment as an outpatient [<a href="#rid46">46</a>]. Due primarily to it long half-life, the dosing interval for <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> can be extended to three times weekly (ie, 5 mg/kg three times weekly) [<a href="#rid85">85</a>]. However, the majority of reports utilizing liposomal amphotericin B are for prevention of invasive fungal infection (see below).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylaxis (when other agents cannot be used) </strong>−<strong> </strong>Use of intravenous liposomal formulations of amphotericin B (most notably <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a>) for prevention of invasive fungal infections is generally restricted to situations in which azole-based strategies are limited by drug interactions (most notably <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, and/or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>) or toxicity [<a href="#rid86">86</a>]. </p><p></p><p class="bulletIndent1">The optimal dosing regimen is not known. Lower doses of <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (2 to 5 mg/kg) and extended dosing intervals (most commonly 2 to 3 times weekly) have been reported to reduce fungal colonization but not invasive fungal infections in patients with hematologic malignancies undergoing chemotherapy or bone marrow transplantation [<a href="#rid87">87</a>]. Weekly high-dose (ie, 10 mg/kg) liposomal amphotericin B has been reported to be safe and effective for the prevention of invasive fungal infections in some studies, but others have reported toxicity and/or increases in invasive fungal infections with such regimens [<a href="#rid88">88-93</a>]. Thus, weekly high-dose therapy is not recommended. Because the balance between efficacy and toxicity is delicate, a specialist should be consulted when designing a prophylactic regimen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other alternative regimens </strong>− A randomized trial examining the impact of escalating the doses of <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> to 10 mg/kg per day for the first two weeks of therapy in patients with invasive mold infections (mostly invasive aspergillosis) demonstrated increases in treatment-related nephrotoxicity without increased efficacy compared with dosing of 3 mg/kg per day [<a href="#rid94">94</a>]. </p><p></p><p class="bulletIndent1">The need for dose escalations (up to 10mg/kg/day of <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a>) have been discussed for the treatment of select, invasive infections such as mucormycosis [<a href="#rid95">95,96</a>]. In such settings, the full target dose should be administered at the initiation of therapy (rather than titrated over several days). (See  <a class="medical medical_review" href="/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>.)</p><p></p><p>For treatment of cryptococcal meningitis, preliminary data suggested that <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> at doses of 10 mg/kg/day were well-tolerated and could allow for less frequent dosing or shorter courses of therapy [<a href="#rid97">97</a>]. A phase 3 randomized, controlled, noninferiority trial conducted in Africa reported that a single IV dose of liposomal amphotericin B,10mg/kg/day, combined with <a class="drug drug_general" data-topicid="8451" href="/d/drug information/8451.html" rel="external">flucytosine</a> and <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> for 14 days as initial induction therapy was as effective as standard therapy of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> plus flucytosine for seven days followed by fluconazole for seven days for the treatment of cryptococcal meningitis in patients with HIV (see  <a class="medical medical_review" href="/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention"</a>) [<a href="#rid98">98</a>]. Dosing for specific indications is discussed in specific UpToDate topics and in Lexicomp drug monographs.</p><p class="headingAnchor" id="H20"><span class="h2">Availability and cost</span><span class="headingEndMark"> — </span>A 2016 investigation of the availability of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> worldwide reported that the drug was not licensed or available in 22 of 155 (14.2 percent) and 42 of 155 (27.1 percent) of the countries surveyed, respectively [<a href="#rid99">99</a>]. In this report, the daily cost of amphotericin B deoxycholate amphotericin B ranged from &lt;$1 to $171 (USD).</p><p>The drug acquisition cost of a lipid-based formulation of amphotericin B is significantly higher than that of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> and may exceed $200 per day (depending upon the formulation and contract pricing). Pharmacoeconomic analyses have been performed to assess whether or not this increase in cost compared with amphotericin B deoxycholate can be offset by reductions in toxicity and the costs associated with adverse reactions. In one such study, a multicenter trial of 414 patients with febrile neutropenia showed that hospital costs were significantly higher for the group receiving <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> compared with amphotericin B deoxycholate as first-line empiric therapy ($48,962 versus $43,184) based upon the cost of the drug [<a href="#rid100">100</a>]. However, when the cost of the study drug was excluded, hospital costs were lower for the liposomal amphotericin B group, which was probably due to the increased cost of the management of the nephrotoxicity associated with amphotericin B deoxycholate. The authors concluded that both drug cost and risks for nephrotoxicity impact the cost-effectiveness of liposomal amphotericin B.</p><p>Similar conclusions have been reached in analysis of <a class="drug drug_general" data-topicid="8724" href="/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> in HIV-infected patients for the treatment of cryptococcal meningitis [<a href="#rid101">101,102</a>]. Most recently, costs and resource use data were collected from 814 patients enrolled in the AMBITION-cm trial from hospitals in Botswana, Malawi, South Africa, Uganda, and Zimbabwe [<a href="#rid102">102</a>]. Mean total costs were USD $1369 (95% CI 1314 to 1424) and $1237 (1181 to 1293) per participant in the AmBisome and control groups, respectively. The incremental cost-effectiveness ratio was $128 (59 to 257) per life-year saved. </p><p class="headingAnchor" id="H21"><span class="h2">Amphotericin B plus fat emulsions</span><span class="headingEndMark"> — </span>It has been suggested that mixing <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> with fat emulsions may reduce renal dysfunction [<a href="#rid60">60</a>] and infusion-related reactions. However, incomplete and conflicting data exist regarding the safety, efficacy, and stability of these mixtures [<a href="#rid103">103</a>]. Thus, their use should be considered investigational and is discouraged.</p><p class="headingAnchor" id="H22"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>The following interactions are of particular concern with the use of amphotericin B:</p><p class="bulletIndent1"><span class="glyph">●</span>Amphotericin B should not be given concurrently or sequentially with other nephrotoxic agents, if possible. (See  <a class="medical medical_review" href="/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients receiving <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> or skeletal muscle relaxants may be predisposed to toxicity or enhanced effect of these agents following amphotericin B-induced hypokalemia. (See  <a class="medical medical_review" href="/d/html/944.html" rel="external">"Cardiac arrhythmias due to digoxin toxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are data linking amphotericin B and acute pulmonary reactions in patients receiving concomitant leukocyte transfusions, but these reactions also can occur without administering leukocyte transfusions. Infusions of amphotericin B should be separated as far apart as possible from leukocyte transfusions whenever possible [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H5151417"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – Amphotericin B is a polyene antifungal agent with activity in vitro against a wide variety of fungal pathogens. Amphotericin B exerts its antifungal effect by disruption of fungal cell wall synthesis because of its ability to bind to sterols, primarily ergosterol, which leads to the formation of pores that allow leakage of cellular components. Amphotericin B is generally considered cidal against susceptible fungi at clinically relevant concentrations. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of activity</strong> – Activity of amphotericin B has been demonstrated in vitro against a wide variety of clinical fungal isolates, including most <em>Candida</em> spp, <em>Aspergillus </em>spp, the Mucorales, all of the endemic mycoses, and most hyaline and brown-black molds. Activity has also been demonstrated against <em>Leishmania </em>spp. Organisms that are usually resistant to amphotericin B include the organisms that cause chromoblastomycosis as well as <em>Aspergillus terreus</em>, <em>Candida lusitaniae</em>, <em>Scedosporium </em>spp, and some <em>Fusarium </em>spp. (See <a class="local">'Spectrum of activity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient-population</strong> – Because of the toxicities associated with its intravenous use along with the expanded availability of safer treatment options, amphotericin B is frequently reserved for patients who have severe, life-threatening invasive fungal infections or who are unable to tolerate alternative antifungal agents. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Route of administration</strong> – The drug is poorly absorbed (less than 5 percent) after oral administration. As a result, treatment of systemic mycoses requires intravenous administration. (See <a class="local">'Absorption'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood levels</strong> – Serum concentrations are not influenced by hepatic or renal function or by hemodialysis or peritoneal dialysis. (See <a class="local">'Metabolism/elimination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Infusion-related reactions, particularly nausea and vomiting, are common with <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> administration. Drug-induced fever, chills, and headache can also be seen. Medications can be given prior to amphotericin B administration to minimize or prevent these adverse effects. (See <a class="local">'Infusion-related reactions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, a reversible and often transient decline in glomerular filtration rate (GFR) has been described. Volume expansion with intravenous sodium chloride (a practice commonly known as "sodium loading") may ameliorate the decline in GFR; 500 mL of 0.9 percent sodium chloride is typically given prior to the amphotericin B infusion. (See <a class="local">'Nephrotoxicity'</a> above and  <a class="medical medical_review" href="/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypokalemia, hypomagnesemia, and hyperchloremic acidosis are reflections of an increase in distal tubular membrane permeability. Many patients require potassium and/or magnesium supplementation during therapy. (See <a class="local">'Electrolyte abnormalities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lipid-based formulations of amphotericin B have been introduced in an attempt to reduce the toxicities associated with <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>. The lipid formulations of amphotericin B are substantially less nephrotoxic than amphotericin B deoxycholate. The pharmacokinetics of these preparations differ significantly from amphotericin B deoxycholate and each other. (See <a class="local">'Lipid-based amphotericin B formulations'</a> above and  <a class="medical medical_review" href="/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity", section on 'Use of lipid-based formulations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The recommended dosing of the various formulations of amphotericin B for specific fungal diseases is discussed in detail in UpToDate topics and Lexi-Comp drug monographs. (See <a class="local">'Introduction'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dismukes WE. Antifungal therapy: lessons learned over the past 27 years. Clin Infect Dis 2006; 42:1289.</a></li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Maertens J, Pagano L, Azoulay E, Warris A. Liposomal amphotericin B-the present. J Antimicrob Chemother 2022; 77:ii11.</a></li><li><a class="nounderline abstract_t">Escribano P, Mesquida A, López-Montesinos S, et al. Amphotericin B, itraconazole, posaconazole, and isavuconazole MICs against clinical Mucorales isolates obtained by visual inspection and spectrophotometric reading according to the EUCAST 9.4 procedure. Med Mycol 2023; 61.</a></li><li class="breakAll">McEvoy G (Ed). American Hospital Formulary Service — 1996. American Society of Health System Pharmacists, Bethesda, MD, 1996.</li><li><a class="nounderline abstract_t">Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002; 359:1135.</a></li><li><a class="nounderline abstract_t">Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39:192.</a></li><li><a class="nounderline abstract_t">Meletiadis J, Meis JF, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46:62.</a></li><li><a class="nounderline abstract_t">Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20:695.</a></li><li class="breakAll">Candida auris. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/fungal/candida-auris/index.html (Accessed on March 31, 2021).</li><li class="breakAll">Antifungal Susceptibility Testing and Interpretation. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.htm (Accessed on May 03, 2023).</li><li><a class="nounderline abstract_t">Jaggavarapu S, Burd EM, Weiss DS. Micafungin and amphotericin B synergy against Candida auris. Lancet Microbe 2020; 1:e314.</a></li><li><a class="nounderline abstract_t">O'Brien B, Liang J, Chaturvedi S, et al. Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations. Lancet Microbe 2020; 1:e193.</a></li><li><a class="nounderline abstract_t">Stone NR, Bicanic T, Salim R, Hope W. Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs 2016; 76:485.</a></li><li><a class="nounderline abstract_t">Groll AH, Piscitelli SC, Walsh TJ. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy 2001; 21:133S.</a></li><li><a class="nounderline abstract_t">Drew RH. Aerosol and other novel administrations for prevention and treatment of invasive aspergillosis. Med Mycol 2009; 47 Suppl 1:S355.</a></li><li><a class="nounderline abstract_t">Safdar A, Rodriguez GH. Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation. Pharmacotherapy 2013; 33:1035.</a></li><li><a class="nounderline abstract_t">Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001; 45:922.</a></li><li><a class="nounderline abstract_t">Wiederhold NP, Tam VH, Chi J, et al. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50:469.</a></li><li><a class="nounderline abstract_t">Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983; 8:17.</a></li><li><a class="nounderline abstract_t">Stott KE, Beardsley J, Whalley S, et al. Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165:891.</a></li><li><a class="nounderline abstract_t">Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 97:509.</a></li><li class="breakAll">Infectious Diseases Society of America. http://www.idsociety.org/Index.aspx (Accessed on April 16, 2015).</li><li><a class="nounderline abstract_t">Drew RH, Perfect JR. Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement. J Fungi (Basel) 2022; 8.</a></li><li><a class="nounderline abstract_t">Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308.</a></li><li><a class="nounderline abstract_t">Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 322:579.</a></li><li><a class="nounderline abstract_t">Geersing TH, Franssen EJF, Spronk PE, et al. Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching. J Antimicrob Chemother 2021; 77:246.</a></li><li><a class="nounderline abstract_t">Leu HS, Huang CT. Clearance of funguria with short-course antifungal regimens: a prospective, randomized, controlled study. Clin Infect Dis 1995; 20:1152.</a></li><li><a class="nounderline abstract_t">Jacobs LG, Skidmore EA, Freeman K, et al. Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients. Clin Infect Dis 1996; 22:30.</a></li><li><a class="nounderline abstract_t">Jacobs LG. Fungal urinary tract infections in the elderly: treatment guidelines. Drugs Aging 1996; 8:89.</a></li><li><a class="nounderline abstract_t">Fan-Havard P, O'Donovan C, Smith SM, et al. Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis 1995; 21:960.</a></li><li><a class="nounderline abstract_t">Stevens DA, Shatsky SA. Intrathecal amphotericin in the management of coccidioidal meningitis. Semin Respir Infect 2001; 16:263.</a></li><li><a class="nounderline abstract_t">Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005; 41:1217.</a></li><li><a class="nounderline abstract_t">Keane JR. Cisternal puncture complications. Treatment of coccidioidal meningitis with amphotericin B. Calif Med 1973; 119:10.</a></li><li><a class="nounderline abstract_t">Godet C, Couturaud F, Marchand-Adam S, et al. Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial. Eur Respir J 2022; 59.</a></li><li><a class="nounderline abstract_t">Hayes D Jr, Murphy BS, Lynch JE, Feola DJ. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatr Pulmonol 2010; 45:1145.</a></li><li><a class="nounderline abstract_t">Hanada S, Uruga H, Takaya H, et al. Nebulized liposomal amphotericin B for treating Aspergillus empyema with bronchopleural fistula. Am J Respir Crit Care Med 2014; 189:607.</a></li><li><a class="nounderline abstract_t">Krzywda EA, Andris DA, Edmiston CE Jr, Quebbeman EJ. Treatment of Hickman catheter sepsis using antibiotic lock technique. Infect Control Hosp Epidemiol 1995; 16:596.</a></li><li><a class="nounderline abstract_t">Benoit JL, Carandang G, Sitrin M, Arnow PM. Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. Clin Infect Dis 1995; 21:1286.</a></li><li><a class="nounderline abstract_t">Johnson DC, Johnson FL, Goldman S. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr Infect Dis J 1994; 13:930.</a></li><li><a class="nounderline abstract_t">Angel-Moreno A, Boronat M, Bolaños M, et al. Candida glabrata fungemia cured by antibiotic-lock therapy: case report and short review. J Infect 2005; 51:e85.</a></li><li><a class="nounderline abstract_t">Viale P, Petrosillo N, Signorini L, et al. Should lock therapy always be avoided for central venous catheter-associated fungal bloodstream infections? Clin Infect Dis 2001; 33:1947.</a></li><li><a class="nounderline abstract_t">Wu CY, Lee PI. Antibiotic-lock therapy and erythromycin for treatment of catheter-related Candida parapsilosis and Staphylococcus aureus infections. J Antimicrob Chemother 2007; 60:706.</a></li><li><a class="nounderline abstract_t">Arnow PM, Kushner R. Malassezia furfur catheter infection cured with antibiotic lock therapy. Am J Med 1991; 90:128.</a></li><li><a class="nounderline abstract_t">van Eck van der Sluijs A, Eekelschot KZ, Frakking FN, et al. Salvage of the peritoneal dialysis catheter in Candida peritonitis using amphotericin B catheter lock. Perit Dial Int 2021; 41:110.</a></li><li><a class="nounderline abstract_t">McGhee W, Michaels MG, Martin JM, et al. Antifungal Lock Therapy with Liposomal Amphotericin B: A Prospective Trial. J Pediatric Infect Dis Soc 2016; 5:80.</a></li><li><a class="nounderline abstract_t">Castagnola E, Marazzi MG, Tacchella A, Giacchino R. Broviac catheter-related candidemia. Pediatr Infect Dis J 2005; 24:747.</a></li><li><a class="nounderline abstract_t">Buckler BS, Sams RN, Goei VL, et al. Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy. Pediatr Infect Dis J 2008; 27:762.</a></li><li><a class="nounderline abstract_t">Gigliotti F, Shenep JL, Lott L, Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J Infect Dis 1987; 156:784.</a></li><li><a class="nounderline abstract_t">Yamazaki H, Kondo T, Aoki K, et al. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis. Diagn Microbiol Infect Dis 2018; 90:123.</a></li><li><a class="nounderline abstract_t">Falci DR, da Rosa FB, Pasqualotto AC. Hematological toxicities associated with amphotericin B formulations. Leuk Lymphoma 2015; 56:2889.</a></li><li><a class="nounderline abstract_t">Baracaldo-Santamaría D, Cala-Garcia JD, Medina-Rincón GJ, et al. Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation? Antibiotics (Basel) 2022; 11.</a></li><li><a class="nounderline abstract_t">Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27:603.</a></li><li><a class="nounderline abstract_t">Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 1999; 19:306.</a></li><li><a class="nounderline abstract_t">Steimbach LM, Tonin FS, Virtuoso S, et al. Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis. Mycoses 2017; 60:146.</a></li><li><a class="nounderline abstract_t">Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22 Suppl 2:S133.</a></li><li><a class="nounderline abstract_t">Graybill JR. Lipid formulations for amphotericin B: does the emperor need new clothes? Ann Intern Med 1996; 124:921.</a></li><li><a class="nounderline abstract_t">Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383.</a></li><li><a class="nounderline abstract_t">Mistro S, Maciel Ide M, de Menezes RG, et al. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis 2012; 54:1774.</a></li><li><a class="nounderline abstract_t">Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137:105.</a></li><li><a class="nounderline abstract_t">Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764.</a></li><li><a class="nounderline abstract_t">Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31:1155.</a></li><li><a class="nounderline abstract_t">Sidhu R, Lash DB, Heidari A, et al. Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Adler-Moore J, Lewis RE, Brüggemann RJM, et al. Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. Clin Infect Dis 2019; 68:S244.</a></li><li><a class="nounderline abstract_t">Roden MM, Nelson LD, Knudsen TA, et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin Infect Dis 2003; 36:1213.</a></li><li><a class="nounderline abstract_t">Johnson MD, Drew RH, Perfect JR. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy 1998; 18:1053.</a></li><li><a class="nounderline abstract_t">Loo AS, Muhsin SA, Walsh TJ. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. Expert Opin Drug Saf 2013; 12:881.</a></li><li><a class="nounderline abstract_t">Farmakiotis D, Tverdek FP, Kontoyiannis DP. The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B. Clin Infect Dis 2013; 56:701.</a></li><li class="breakAll">Food and Drug Administration. AmBisome (amphotericin B) liposome for injection. Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2012. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm299520.htm.</li><li><a class="nounderline abstract_t">Delanghe JR, Himpe J, Boelens J, et al. C-reactive protein interacts with amphotericin B liposomes and its potential clinical consequences. Clin Chem Lab Med 2023; 61:1065.</a></li><li><a class="nounderline abstract_t">Groll AH, Rijnders BJA, Walsh TJ, et al. Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clin Infect Dis 2019; 68:S260.</a></li><li><a class="nounderline abstract_t">Wasmann RE, Smit C, van Dongen EPH, et al. Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals. Clin Infect Dis 2020; 70:2213.</a></li><li><a class="nounderline abstract_t">Heinemann V, Bosse D, Jehn U, et al. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob Agents Chemother 1997; 41:1275.</a></li><li><a class="nounderline abstract_t">Van Daele R, Wauters J, Elkayal O, et al. Liposomal amphotericin B exposure in critically ill patients: a prospective pharmacokinetic study. Med Mycol 2022; 60.</a></li><li><a class="nounderline abstract_t">Weiler S, Bellmann-Weiler R, Joannidis M, Bellmann R. Penetration of amphotericin B lipid formulations into pleural effusion. Antimicrob Agents Chemother 2007; 51:4211.</a></li><li><a class="nounderline abstract_t">Seibel NL, Shad AT, Bekersky I, et al. Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45:3487.</a></li><li><a class="nounderline abstract_t">Stott KE, Moyo M, Ahmadu A, et al. Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis. J Antimicrob Chemother 2022; 78:276.</a></li><li><a class="nounderline abstract_t">Zhao Y, Seelhammer TG, Barreto EF, Wilson JW. Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation. Pharmacotherapy 2020; 40:89.</a></li><li><a class="nounderline abstract_t">Servais R, Ammar MA, Gurnani PK. Treatment of pulmonary blastomycosis with high-dose liposomal amphotericin B in a patient receiving extracorporeal membrane oxygenation. BMJ Case Rep 2019; 12.</a></li><li><a class="nounderline abstract_t">Nix DE, Hayes JF, Al Obaidi M, Zangeneh T. Fixed Dosing of Amphotericin B in Morbidly Obese Individuals. Clin Infect Dis 2021; 72:e431.</a></li><li><a class="nounderline abstract_t">Ting MH, Spec A, Micek ST, et al. Evaluation of Total Body Weight versus Adjusted Body Weight Liposomal Amphotericin B Dosing in Obese Patients. Antimicrob Agents Chemother 2021; 65:e0236620.</a></li><li><a class="nounderline abstract_t">O'Grady N, McManus D, Briggs N, et al. Dosing implications for liposomal amphotericin B in pregnancy. Pharmacotherapy 2023; 43:452.</a></li><li><a class="nounderline abstract_t">van de Peppel RJ, Schauwvlieghe A, Van Daele R, et al. Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B. Med Mycol 2020; 58:874.</a></li><li><a class="nounderline abstract_t">Batchelor R, Thomas C, Gardiner BJ, et al. When azoles cannot be used: the clinical effectiveness of intermittent liposomal amphotericin prophylaxis in haematology patients. Open Forum Infect Dis 2021.</a></li><li><a class="nounderline abstract_t">Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23:163.</a></li><li><a class="nounderline abstract_t">Giannella M, Ercolani G, Cristini F, et al. High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial. Transplantation 2015; 99:848.</a></li><li><a class="nounderline abstract_t">Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31:135.</a></li><li><a class="nounderline abstract_t">Annino L, Chierichini A, Anaclerico B, et al. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia. Antimicrob Agents Chemother 2013; 57:2596.</a></li><li><a class="nounderline abstract_t">El-Cheikh J, Faucher C, Fürst S, et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39:301.</a></li><li><a class="nounderline abstract_t">Mehta P, Vinks A, Filipovich A, et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2006; 12:235.</a></li><li><a class="nounderline abstract_t">Luu Tran H, Mahmoudjafari Z, Rockey M, et al. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease. J Oncol Pharm Pract 2016; 22:228.</a></li><li><a class="nounderline abstract_t">Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44:1289.</a></li><li><a class="nounderline abstract_t">Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother 2015; 70:3116.</a></li><li><a class="nounderline abstract_t">Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19:e405.</a></li><li><a class="nounderline abstract_t">Jarvis JN, Leeme TB, Molefi M, et al. Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. Clin Infect Dis 2019; 68:393.</a></li><li><a class="nounderline abstract_t">Jarvis JN, Lawrence DS, Meya DB, et al. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. N Engl J Med 2022; 386:1109.</a></li><li><a class="nounderline abstract_t">Kneale M, Bartholomew JS, Davies E, Denning DW. Global access to antifungal therapy and its variable cost. J Antimicrob Chemother 2016; 71:3599.</a></li><li><a class="nounderline abstract_t">Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000; 18:2476.</a></li><li><a class="nounderline abstract_t">Tuon FF, Florencio KL, Rocha JL. Burden of acute kidney injury in HIV patients under deoxycholate amphotericin B therapy for cryptococcal meningitis and cost-minimization analysis of amphotericin B lipid complex. Med Mycol 2019; 57:265.</a></li><li><a class="nounderline abstract_t">Lawrence DS, Muthoga C, Meya DB, et al. Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial. Lancet Glob Health 2022; 10:e1845.</a></li><li><a class="nounderline abstract_t">Sievers TM, Kubak BM, Wong-Beringer A. Safety and efficacy of Intralipid emulsions of amphotericin B. J Antimicrob Chemother 1996; 38:333.</a></li></ol></div><div id="topicVersionRevision">Topic 476 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16586389" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Antifungal therapy: lessons learned over the past 27 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36426672" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Liposomal amphotericin B-the present.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37113026" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Amphotericin B, itraconazole, posaconazole, and isavuconazole MICs against clinical Mucorales isolates obtained by visual inspection and spectrophotometric reading according to the EUCAST 9.4 procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37113026" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Amphotericin B, itraconazole, posaconazole, and isavuconazole MICs against clinical Mucorales isolates obtained by visual inspection and spectrophotometric reading according to the EUCAST 9.4 procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11943280" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antifungal drug resistance of pathogenic fungi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307028" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11751112" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17934079" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fusarium infections in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17934079" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Fusarium infections in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17934079" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fusarium infections in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35544183" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Micafungin and amphotericin B synergy against Candida auris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35544199" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26818726" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11501987" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18654913" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Aerosol and other novel administrations for prevention and treatment of invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23784915" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11181381" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16436698" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6301738" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical pharmacokinetics of systemic antifungal drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29735567" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1569339" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7985709" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The prophylactic use of low-dose amphotericin B in bone marrow transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7985709" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The prophylactic use of low-dose amphotericin B in bone marrow transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35205966" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2184499" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Amphotericin B: 30 years of clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238151" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34613383" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7619991" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clearance of funguria with short-course antifungal regimens: a prospective, randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8824962" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8845590" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fungal urinary tract infections in the elderly: treatment guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8645847" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11740828" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Intrathecal amphotericin in the management of coccidioidal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16206093" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4741057" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cisternal puncture complications. Treatment of coccidioidal meningitis with amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34764182" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20658484" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24579838" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Nebulized liposomal amphotericin B for treating Aspergillus empyema with bronchopleural fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8568206" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Treatment of Hickman catheter sepsis using antibiotic lock technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589156" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7854895" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230210" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Candida glabrata fungemia cured by antibiotic-lock therapy: case report and short review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692310" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Should lock therapy always be avoided for central venous catheter-associated fungal bloodstream infections?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17623689" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Antibiotic-lock therapy and erythromycin for treatment of catheter-related Candida parapsilosis and Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1986581" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Malassezia furfur catheter infection cured with antibiotic lock therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32400305" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Salvage of the peritoneal dialysis catheter in Candida peritonitis using amphotericin B catheter lock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908494" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Antifungal Lock Therapy with Liposomal Amphotericin B: A Prospective Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16094241" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Broviac catheter-related candidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18664989" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3309074" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29203252" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25629990" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hematological toxicities associated with amphotericin B formulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35625289" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9770163" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Lipid formulations of amphotericin B: clinical efficacy and toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10221369" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lipid-based amphotericin B for the treatment of fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27878878" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8722841" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Lipid formulations of amphotericin B: recent progress and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8610924" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Lipid formulations for amphotericin B: does the emperor need new clothes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9636868" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491505" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118965" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10072411" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073745" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29686150" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31222254" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12746764" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9758315" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23931455" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23166189" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23166189" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36691951" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : C-reactive protein interacts with amphotericin B liposomes and its potential clinical consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31222253" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31588493" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9174183" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36124725" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Liposomal amphotericin B exposure in critically ill patients: a prospective pharmacokinetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785511" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Penetration of amphotericin B lipid formulations into pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27855062" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11709329" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36411251" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31742741" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31253662" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Treatment of pulmonary blastomycosis with high-dose liposomal amphotericin B in a patient receiving extracorporeal membrane oxygenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32725197" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Fixed Dosing of Amphotericin B in Morbidly Obese Individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34125591" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Evaluation of Total Body Weight versus Adjusted Body Weight Liposomal Amphotericin B Dosing in Obese Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36862037" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Dosing implications for liposomal amphotericin B in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31965178" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : When azoles cannot be used: the clinical effectiveness of intermittent liposomal amphotericin prophylaxis in haematology patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10197802" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25531982" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162375" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23529741" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17262059" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443521" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25471252" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443465" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26316385" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31699664" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29945252" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35320642" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27516477" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Global access to antifungal therapy and its variable cost.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10856108" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29762761" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Burden of acute kidney injury in HIV patients under deoxycholate amphotericin B therapy for cryptococcal meningitis and cost-minimization analysis of amphotericin B lipid complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36400090" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8889711" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Safety and efficacy of Intralipid emulsions of amphotericin B.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
